Black Cat Bio

Black Cat Bio is a pre-clinical stage biotechnology company focused on developing next-generation chimeric antigen receptor T-cell (CAR-T) therapies for the treatment of solid tumors. Founded by industry veteran Laurence Cooper, the company leverages non-viral gene transfer technologies to create more efficient and scalable cell therapies. Their approach aims to overcome the limitations of traditional viral-based CAR-T manufacturing, potentially reducing costs and improving patient access. The company's pipeline is primarily directed toward difficult-to-treat solid malignancies using a proprietary engineering platform. Black Cat Bio represents a new venture in the cell therapy space, building on decades of expertise in non-viral transposon systems.